Discover 1 curated intelligence briefings related to this specific topic.
While the oncology molecular diagnostic market races toward an 8.5 billion dollar valuation, a June 2026 wave of insurance tax hikes and trillion-dollar credit card debts are making the cost of survival a luxury.
